title: Impact of the U.S. Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugs.
authors.affiliation: AstraZeneca, Wilmington, Delaware, USA. boaz.hirshberg@astrazeneca.com
authors.forename: Boaz
authors.initials: B
authors.lastname: Hirshberg
authors.forename: Itamar
authors.initials: I
authors.lastname: Raz
mesh_terms: D002319:Cardiovascular System / Q000187:drug effects; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence*
chemical_list: D007004:Hypoglycemic Agents